Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Mcburnzon Jan 13, 2020 11:00am

103 Views

Post# 30546298

RE:Clearly its only 5 sites out of 54 that have a glitch

In the end of the day they reduced trigs by over 30 % wich I was thinking would be a home run and excellent...this is so bizarre that something obviously went wrong or triglycerides just do what they want up and down ect randomly.....management should really put out more data in regards to if they met endpoints minus those 5 sites ect. This is bad situation none the less.

Bullboard Posts

Changing Europe’s dependency on HREE from China